IND
NTS231 (NRF2 degrader)
Nutshell Therapeutics: company profile
IND in effect (FDA) per company
Since , the date of the source that reports this phase.
Summary
NTS231 is a NRF2 degrader from Nutshell Therapeutics. The source describes it as small molecule degrader. It is being developed for cancers with aberrant NRF2 activation. Per the company, it was at IND in effect (FDA) as of Sep 25, 2026. The AI role named in the source is molecule design. The latest dated source is from Sep 25, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Nutshell Therapeutics
- Indication
- Cancers with aberrant NRF2 activation
- Therapeutic area
- Other
- Modality
- Small molecule degrader
- AI role
- Molecule design
- Phase in the source
- IND in effect (FDA), as of Sep 25, 2026
- Phase source
- Confirmed
- Board column
- IND
- Trial record
- none found on CT.gov or EU CTIS; China registries not reachable
AI evidence
AI source: Company
“The discovery of NTS231 was powered by Nutshell Therapeutics' proprietary AI-driven allosteric drug discovery platform, ALLOSTAR™”
Milestone timeline
-
Company release: IND in effect (FDA)
Spot an error? Tell me and I'll fix it.